Pharmacology - PowerPoint PPT Presentation

1 / 24
About This Presentation
Title:

Pharmacology

Description:

Pharmacologic sites of action Dopamine (DA) Norepinephrine (NE) Serotonin (5HT) ... Prozac, Zoloft, Luvox, Paxil, Serzone, Desyrel (trazodone), Celexa, Lexapro ... – PowerPoint PPT presentation

Number of Views:620
Avg rating:3.0/5.0
Slides: 25
Provided by: Gre45
Category:

less

Transcript and Presenter's Notes

Title: Pharmacology


1
Pharmacology Brain Injury
  • Gregory J. OShanick, M.D.
  • National Medical Director,
  • Brain Injury Association of America
  • Medical Director,
  • Center for Neurorehabilitation Services,
  • Richmond, VA

2
Lobes of the brain
3
(No Transcript)
4
Neurochemistry basics
  • Neuronal function
  • Neurotransmitters in CNS
  • Pharmacologic sites of action Dopamine
    (DA) Norepinephrine (NE) Serotonin
    (5HT) GABA Acetylcholine
    (ACh) Endorphin/ Enkephlin (ED)

5
(No Transcript)
6
(No Transcript)
7
Pathophysiology of TBI
  • Shear- strain forces cause mechanical diffuse
    axonal injury
  • Glutamate release followed by metabolic
    depression causes later onset DAI
  • Focal contusions and bony prominences
  • Increased intracranial pressure/edema
  • Mass effects EDH, SDH, ICH
  • Excitotoxin cascade

8
(No Transcript)
9
(No Transcript)
10
Neurotransmitter changes after TBI
  • Activity correlates with better outcome
  • Increased catecholamine activity correlates with
    better outcome
  • Decreased serotonergic activity noted in frontal
    contused/agitated
  • Decline in catecholamine activity over time

11
Neuropharmacology and Brain Injury
  • Predicated on studies in other populations
  • Few large, well-designed RCTs in brain injury
  • Uses are off label
  • Treatment of co-morbid or pre-morbid conditions
  • Third party reimbursement problems
  • Patient assistance program complexities

12
Classes of agents used in brain injury
  • Anticonvulsants
  • Antispasticity agents
  • Antidepressants
  • Antianxiety agents
  • Antipsychotics
  • Antiparkinsonian agents
  • Anti-impulsivity/Antimanic agents
  • Opiate antagonists
  • Cognitive enhancers

13
AnticonvulsantsTypes and Target Symptoms
  • Tegretol, Carbatrol (carbamazepine)
  • Trileptal (oxcarbazepine)
  • Dilantin (phenytoin)
  • Depakote (valproic acid)
  • Neurontin (gabapentin)
  • Klonopin (clonazepam)
  • Lamictal (lamotrigine)
  • Topamax (topiramate)
  • Keppra (levetiracetam)
  • Zonegran (zonisamide)
  • Lyrica (pregabalin)
  • Phenobarbital
  • Posttraumatic seizures
  • Epilepsy spectrum disorder
  • Posttraumatic headache
  • Intermittent explosive disorder
  • Impulsivity/ mania
  • Positive psychotic symptoms
  • Kluver-Bucy Syndrome
  • Chronic pain syndromes

14
Antispasticity agentsTypes and Target Symptoms
  • Dantrium (dantrolene)
  • Flexeril (cyclobenzaprine)
  • Baclofen (lioreseal)
  • Robaxin (methocarbamol)
  • Skelaxin (metaxolone)
  • Zanaflex (tizanidine)
  • Botox (botulinum toxin)
  • Increased muscle tone
  • Acute muscle spasm
  • Headache due to muscle tension

15
AntidepressantsTypes and Target Symptoms
  • Tricyclics imipramine, amitriptyline,
    nortriptyline, desipramine, clomipramine,
    doxepin, amoxapine
  • Tetracyclics maprotiline (Ludiomil)
  • SSRI Prozac, Zoloft, Luvox, Paxil, Serzone,
    Desyrel (trazodone), Celexa, Lexapro
  • SNRI Effexor, Cymbalta, Pristiq
  • Bupropion (Wellbutrin, Zyban)
  • Mirtazapine (Remeron)
  • MAO Inhibitors Nardil, Parnate
  • Neurovegetative symptoms IN SAD CAGES
  • Post traumatic stress disorder
  • DIMS
  • Enuresis
  • Explosive episodes
  • Chronic pain syndromes
  • Migraine prophylaxis

16
Antianxiety agentsTypes and Target Symptoms
  • Benzodiazepines Ativan, Valium, Xanax, Librium,
    Tranxene, Klonopin, Halcion, Restoril, Dalmane
  • Buspirone (Buspar)
  • Hydroxyzine (Atarax, Vistaril)
  • Initial insomnia
  • Anticipatory anxiety
  • Spasticity
  • Seizure
  • Acute aggressive behavior
  • Chronic agitation (buspirone)
  • Ethanol detox (except buspirone)

17
PsychostimulantsTypes and Target Symptoms
  • methylphenidate (Ritalin, Concerta, Metadate,
    Daytrana)
  • d-amphetamine (Dexedrine)
  • dexmethylphenidate (Focalin)
  • amphetamine salts (Adderall)
  • lisdexamfetamine (Vyvanse)
  • atomoxetine (Strattera)
  • modafanil (Provigil)
  • Decreased attention/concentration
  • Fatigue
  • Narcolepsy / posttraumatic sleep disorder
  • Apathy/amotivation

18
Anti-impulsivity(antimanic)agentsTypes and
Target Symptoms
  • Lithium
  • Clonidine (Catapres)
  • Propranolol (Inderal)
  • Carbamazepine (Tegretol)
  • Valproic acid (Depakote)
  • Lamotrigine (Lamictal)
  • Olanzepine (Zyprexa)
  • Cyclic mood disorders
  • Refractory mood disorders
  • Aggressive behavior
  • Interictal behavior disturbance

19
Cognitive enhancersTypes and Target Symptoms
  • Cognex (tacrine)
  • Aricept (donepezil)
  • Exelon (rivastigmine)
  • Razadyne (galantamine)
  • Namenda (memantine)
  • Gingko biloba
  • Estrogen
  • Alzheimers disease
  • Vascular dementia
  • Hypoxic brain injury
  • Traumatic brain injury - ? Elders - ? APOE4
    genotypes

20
AntipsychoticsTypes and Target Symptoms
  • Clozapine (Clozaril)
  • Olanzepine (Zyprexa)
  • Quetiapine (Seroquel)
  • Phenothiazines (Thorazine, Mellaril, Compazine,
    Trilafon, Phenergan, Stelazine, Prolixin)
  • Buterophenones (Haldol, Risperdal,
    Geodon)
  • Aripiprazole (Abilify)
  • Vomiting
  • Analgesic potentiation
  • Decreased GI motility
  • Positive psychotic symptoms
  • Agitation / aggression - short term use

21
Antiparkinson agentsTypes and Target Symptoms
  • Dopamine agonists bromocriptine (Parlodel)
    pergolide (Permax)
    ropinirole (ReQuip) pramipexole
    (Mirapex)
  • DA production enhancers L-DOPA
  • DA potentiators amantadine, selegiline
  • Anticholinergics Cogentin, Artane
  • Classic Parkinsons Syndrome
  • ? Initiation /amotivation
  • Dysphagia
  • ?Attention and concentration
  • Fatigue
  • ? cognitive endurance
  • Drooling
  • Vestibular dysfunction
  • Tactile defensiveness
  • Coma

22
Neuropharmacology and Brain Injury
  • Predicated on studies in other populations
  • Few large, well-designed RCTs in brain injury
  • Uses are off label
  • Treatment of co-morbid or pre-morbid conditions
  • Third party reimbursement problems
  • Patient assistance program complexities

23
Therapeutic trial General concepts
  • Adequate drug available to the CNS
  • Duration appropriate to half-life CNS effect
  • Monitor target symptoms (? blinded)
  • Change only one variable at a time
  • If trial (), withdraw agent to assess if
    spontaneous remission or drug effect

24
Thanks for your attention and remember to join
the Brain Injury Association
Write a Comment
User Comments (0)
About PowerShow.com